Acumen Pharmaceuticals (ABOS) financial statements
Net income was -$121M.
Free cash flow was -$116M.
The diluted share count rose 14350% over the period (dilution).
Income statement
Fiscal years, from Acumen Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $8M | $12M | $32M | $42M | $94M | $105M |
| Selling, general and admin | $1M | $7M | $13M | $19M | $20M | $19M |
| Operating income | -$8M | -$20M | -$45M | -$61M | -$114M | -$124M |
| Interest expense | — | — | $0 | $581,000 | $4M | $4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7M | -$101M | -$43M | -$52M | -$102M | -$121M |
| EPS (diluted) | -$17.48 | -$5.02 | -$1.06 | -$1.08 | -$1.71 | -$2.00 |
| Diluted shares | 0M | 20M | 41M | 49M | 60M | 61M |
Balance sheet
Fiscal years, from Acumen Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $44M | $194M | $178M | $244M | $172M | $117M |
| Total current assets | $44M | $199M | $180M | $247M | $178M | $122M |
| Property, plant and equipment | — | $36,000 | $165,000 | $122,000 | $73,000 | $103,000 |
| Total assets | $44M | $230M | $197M | $310M | $239M | $123M |
| Total current liabilities | — | $5M | $8M | $13M | $28M | $30M |
| Total liabilities | $6M | $5M | $8M | $43M | $57M | $52M |
| Shareholders' equity | -$19M | $225M | $189M | $267M | $182M | $70M |
| Net debt | -$44M | -$122M | -$130M | -$67M | -$36M | -$54M |
Cash flow
Fiscal years, from Acumen Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7M | -$18M | -$35M | -$43M | -$86M | -$116M |
| Capital spending | — | $40,000 | $161,000 | $21,000 | $16,000 | $88,000 |
| Free cash flow | — | -$18M | -$35M | -$43M | -$86M | -$116M |
| Stock-based compensation | $154,000 | $922,000 | $3M | $6M | $10M | $10M |
| Net borrowing | — | — | $0 | $30M | $0 | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABOS.
Open ABOS in InvestinglyQuestions
How much free cash flow does Acumen Pharmaceuticals generate?
-$116M in fiscal 2025 (operating cash flow minus capital spending).
From Acumen Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.